ClinicalTrials.gg
RecruitingNCT07558447CHEMOVESUpdated Apr 30, 2026

Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy

An interventional study of CIPN assessment and EV blood analysis in Chemotherapy-Induced Peripheral Neuropathy, Breast Cancer and Gastrointestinal Cancer, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Not applicable, Interventional, and Diagnostic

How we know · 2 judgments

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2025, registered Jan 2026).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Planned enrollment
443rd of 687
120 · median 208
Started
2025
with 61 others
No phase
161 of 887
53 open now
Primary completion
2026-09
later than 153 of 349 live
Registered
851st of 887
by date

Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 443rd largest by planned enrollment of the 687 interventional ones that give a count, is one of 62 that started in 2025, is one of 161 with no phase, reaches primary completion later than 153 of the 349 other live ones, and was the 851st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

226 more — sign in →

All 231 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 887 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN. Participants will be followed from before the start of chemotherapy until six months after treatment ends to evaluate how changes in EVs relate to nerve damage caused by chemotherapy. During the study, participants will provide blood samples before chemotherapy, at the end of treatment, and six months later for measurement and molecular analysis of EVs, will complete questionnaires about neuropathy symptoms, and will undergo simple, non-invasive nerve function tests using a tuning fork (diapason) and a Neuropen device. This study does not test cancer drugs; instead, it aims to identify biological markers in blood that may help predict which patients are at higher risk of developing CIPN, with the goal of improving monitoring and care during cancer treatment.

Read the detailed description

CIPN is a frequent and often long-lasting complication of treatment with several commonly used antineoplastic agents, including taxanes, platinum compounds, and antimitotic drugs. The condition primarily affects sensory neurons of the dorsal root ganglia and peripheral nerve fibers, leading to symptoms such as numbness, tingling, pain, and loss of vibration or tactile sensation. The severity and persistence of CIPN vary markedly between individuals, and currently there are no validated biological markers that allow early identification of patients at increased risk or objective monitoring of neurotoxicity during treatment. As a result, CIPN is usually detected only after clinical symptoms appear, at a stage when nerve damage may already be established and difficult to reverse.

EVs are membrane-bound particles released by virtually all cell types and present in large numbers in biological fluids, including blood. They contain proteins, lipids, and nucleic acids that reflect the physiological and pathological state of their cells of origin. Because EVs can originate from neural and glial cells and can cross biological barriers, they provide a potential window into otherwise inaccessible tissues such as the peripheral nervous system. Changes in EV concentration, membrane composition, and RNA cargo have been reported in several neurological and neurodegenerative conditions, supporting their potential role as circulating indicators of neuronal injury and dysfunction.

This study is designed to evaluate whether longitudinal changes in circulating EVs are associated with the development of CIPN in patients undergoing chemotherapy. Blood samples collected at predefined time points will be used to isolate and quantify EVs and to characterize selected molecular components of their cargo, including membrane lipids and microRNAs. These EV-based measurements will be evaluated in relation to standardized clinical and neurophysiological assessments of peripheral neuropathy performed over the course of treatment and follow-up. By integrating biological and clinical data, the study aims to explore whether EV-derived markers reflect early neurotoxic effects of chemotherapy and whether they may capture individual susceptibility to CIPN.

The study uses a single-group, longitudinal design in which each participant serves as their own reference over time. This approach allows the evaluation of intra-individual changes in EV-related parameters across the different phases of chemotherapy exposure and recovery. It is particularly suited for biomarker discovery in conditions such as CIPN, where baseline inter-individual variability is high and where the key biological signal of interest is the change from an individual's pre-treatment state. This design also avoids the need for a concurrent untreated control group, which would not be ethically or clinically appropriate in this setting.

EVs will be isolated from plasma using standardized protocols designed to preserve vesicle integrity and minimize contamination from non-vesicular particles. Quantitative analysis will be performed to determine the concentration of circulating EVs, expressed as vesicles per microliter, at each study time point. In addition, qualitative analyses will be carried out to investigate specific components of EV cargo that may be relevant to nerve injury and inflammation. These include selected classes of membrane lipids, such as phosphatidylcholine, sphingomyelin, and cholesterol, which are known to influence membrane stability and signaling, as well as microRNAs involved in neuronal function, stress responses, and neuroinflammatory pathways. The combination of quantitative and molecular profiling is intended to provide a multidimensional view of EV dynamics in relation to chemotherapy exposure.

Clinical evaluation of CIPN will be performed using validated symptom-based questionnaires and objective bedside tests of peripheral nerve function. These assessments capture both patient-reported experience and physician-based measures of sensory impairment, allowing a more comprehensive characterization of neurotoxicity than either approach alone. By relating EV-based measurements to these clinical data over time, the study will explore whether changes in EV concentration or composition precede, accompany, or follow the onset of neuropathic symptoms.

Individual susceptibility to CIPN is influenced by multiple factors, including demographic characteristics, pre-existing neuropathy, and genetic background. Although the primary focus of this study is on EV-derived biomarkers, relevant clinical and demographic information will be collected to allow exploratory analyses of how these factors may interact with EV patterns. This will help to distinguish EV changes that are primarily driven by chemotherapy-induced nerve damage from those that reflect underlying patient-specific characteristics.

Because the study does not modify or assign cancer treatments, all oncologic care will proceed according to standard clinical practice. The additional procedures introduced by the study are limited to blood sampling and non-invasive neurological assessments. These procedures are intended solely to support biomarker analysis and phenotypic characterization of CIPN and are not expected to interfere with therapeutic decisions or outcomes.

By focusing on EVs as circulating indicators of peripheral nerve injury, this study aims to generate data that may support the future development of minimally invasive tools for monitoring neurotoxicity in patients receiving chemotherapy. If specific EV-based patterns are found to be associated with CIPN, this could open the way to earlier identification of at-risk individuals and to more personalized management of neurotoxic side effects, with the ultimate goal of improving quality of life for cancer survivors.

03

Conditions studied

  • Chemotherapy-Induced Peripheral Neuropathy
  • Breast Cancer
  • Gastrointestinal Cancer
  • Lung Cancer
  • Urologic Cancer
  • Head and Neck Cancer

Keywords

  • Chemotherapy-Induced Peripheral Neuropathy
  • Neurotoxicity
  • Extracellular Vesicles
  • Biomarkers
  • Liquid Biopsy
  • Paclitaxel
  • Docetaxel
  • Eribulin
  • Capecitabine
  • Carboplatin
  • Oxaliplatin
  • Cisplatin
  • Enfortumab Vedotin
  • Neuropathy
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has signed the form
  • Is 18 years of age or older
  • Is male or female
  • Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care
  • Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care
  • Has lung cancer and is scheduled to receive cisplatin, carboplatin, or docetaxel as part of standard care
  • Has urologic cancer and is scheduled to receive carboplatin, cisplatin, paclitaxel, docetaxel, or enfortumab vedotin as part of standard care
  • Has head and neck cancer and is scheduled to receive carboplatin, paclitaxel, or cisplatin as part of standard care

Exclusion criteria

Exclusion Criteria:

  • Has already been diagnosed with CIPN
  • Has a neurodegenerative disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Baseline (T0)

    Patients eligible to receive antineoplastic compounds with taxanes, platinum compounds, or antimitotic agents, evaluated before the start of chemotherapy (baseline).

    Procedure: CIPN assessment · Other: EV blood analysis

  • Other
    End of Chemotherapy (T1)

    Patients who have completed the planned chemotherapy cycles with taxanes, platinum compounds, or antimitotic agents and are evaluated at the end of treatment.

    Procedure: CIPN assessment · Other: EV blood analysis

  • Other
    Follow-up (T2)

    Patients evaluated six months after completion of chemotherapy.

    Procedure: CIPN assessment · Other: EV blood analysis

Interventions

  • ProcedureCIPN assessment

    Assessment of CIPN using a combination of physician-based and patient-reported measures. Objective evaluation includes assessment of vibration sensitivity. Patient-reported symptoms are assessed using the EORTC-CIPN20 questionnaire (Italian version), a 20-item self-administered questionnaire completed in approximately 10 minutes.

  • OtherEV blood analysis

    Collection of blood samples for isolation, quantification, and molecular characterization of circulating EVs, including analysis of membrane lipid composition and microRNA content.

This study also gives Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Circulating EV Concentration

    Change in the concentration of circulating extracellular vesicles, expressed as vesicles per microliter of plasma, measured by comparing values at the end of chemotherapy (T1) and 6 months after completion of treatment (T2) with baseline at initiation of chemotherapy (T0), in relation to the development of chemotherapy-induced peripheral neuropathy. T1 corresponds to 5 months. T2 corresponds to 6 months after completion of treatment.

    Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)

Secondary outcomes

  1. Change from End of Chemotherapy in Circulating EV Concentration

    Change in the concentration of circulating extracellular vesicles, expressed as vesicles per microliter of plasma, measured by comparing values at the end of chemotherapy (T1) and 6 months after completion of treatment (T2) with baseline at initiation of chemotherapy (T0), in relation to the development of chemotherapy-induced peripheral neuropathy. T1 corresponds to 5 months. T2 corresponds to 6 months after completion of treatment.

    Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)

  2. Changes in EV Membrane Lipid Composition

    The relative abundance of major EV membrane lipid classes-phosphatidylcholine, sphingomyelin, and cholesterol-will be quantified using targeted lipidomic analysis (e.g., mass spectrometry-based lipid profiling). Lipid levels will be expressed as mol (%) within EV samples collected at T0 (baseline), at the end of chemotherapy (T1 corresponding to 5 months) and at T2 (corresponding to 6 months after completion of treatment). Changes in lipid composition over time will be summarized descriptively and compared among time points (T1 vs T1 and T0 vs T2) to assess chemotherapy-associated alterations in EV membrane lipid profiles.

    Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)

  3. Changes in Extracellular Vesicle microRNA Profile

    Changes in the microRNA content of circulating extracellular vesicles measured at T0 (baseline), at the end of chemotherapy (T1 corresponding to 5 months from the initiation of chemotherapy) and at the end of chemotherapy (T2).

    Time frame: 11 months from enrollment (T0), to completion of chemotherapy (T2)

07

Study locations

1 of 1 sites recruiting
  • SC Oncologia Medica Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 20 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Apr 30, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07558447
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Jan 1, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Massimiliano Ruscica, PhD
Contact
massimiliano.ruscica@unimi.it
0039 0250318220
Ornella Garrone, MD
Contact
ornella.garrone@policlinico.mi.it
0039 0255032556
Ornella Garrone, MD
study chair · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Massimiliano Ruscica, PhD
principal investigator · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion